Insulet Corporation $PODD Position Decreased by Sterling Capital Management LLC

Sterling Capital Management LLC reduced its holdings in Insulet Corporation (NASDAQ:PODD) by 93.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 562 shares of the medical instruments supplier’s stock after selling 8,452 shares during the quarter. Sterling Capital Management LLC’s holdings in Insulet were worth $118,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in PODD. Louisiana State Employees Retirement System acquired a new position in shares of Insulet in the 1st quarter worth $755,000. Ritholtz Wealth Management acquired a new position in shares of Insulet in the 1st quarter valued at about $231,000. Fifth Third Wealth Advisors LLC increased its stake in Insulet by 11.2% in the 1st quarter. Fifth Third Wealth Advisors LLC now owns 1,605 shares of the medical instruments supplier’s stock valued at $337,000 after buying an additional 162 shares during the period. OP Asset Management Ltd acquired a new position in shares of Insulet in the first quarter worth $1,513,000. Finally, Banque Cantonale Vaudoise increased its position in Insulet by 68.3% in the 1st quarter. Banque Cantonale Vaudoise now owns 9,870 shares of the medical instruments supplier’s stock worth $2,071,000 after purchasing an additional 4,004 shares during the last quarter.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the stock. Barclays cut their price target on shares of Insulet from $286.00 to $198.00 and set an “underweight” rating on the stock in a report on Thursday, May 7th. Evercore set a $180.00 price objective on Insulet in a research report on Monday. Deutsche Bank Aktiengesellschaft started coverage on Insulet in a research report on Tuesday, June 23rd. They set a “buy” rating and a $190.00 target price on the stock. Truist Financial dropped their price objective on shares of Insulet from $250.00 to $219.00 and set a “buy” rating for the company in a research note on Thursday, June 11th. Finally, Oppenheimer dropped their target price on Insulet from $300.00 to $210.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Twenty-two analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $237.83.

Key Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet launched Omnipod 5 and Omnipod Discover in Spain, expanding access to its tubeless diabetes technology and supporting international growth. Insulet launches Omnipod 5, Omnipod Discover in Spain
• Positive Sentiment: Zacks said Insulet could beat earnings estimates again, citing strong earnings-surprise history and ongoing Omnipod 5 momentum. Why Insulet (PODD) Could Beat Earnings Estimates Again
• Neutral Sentiment: Deutsche Bank initiated coverage on Insulet with a Buy rating and a $190 target, reinforcing a constructive long-term view. Insulet (PODD): Deutsche Bank Initiates Coverage With a Buy and a $190 Target
• Negative Sentiment: Multiple law firms filed or promoted a securities-fraud class action against Insulet, alleging investors were harmed by false or misleading statements during the class period. Pomerantz Law Firm Announces the Filing of a Class Action Against Insulet Corporation and Certain Officers – PODD
• Negative Sentiment: The FDA classified an Omnipod recall as a Class I recall, the most serious level, after injury reports, raising concerns about product safety and potential liability. FDA Classifies Insulet Omnipod Recall as Serious After Injury Reports

Insider Buying and Selling at Insulet

In related news, Director Timothy C. Stonesifer acquired 2,790 shares of the business’s stock in a transaction dated Wednesday, June 3rd. The stock was bought at an average price of $143.51 per share, with a total value of $400,392.90. Following the acquisition, the director owned 9,041 shares in the company, valued at $1,297,473.91. This represents a 44.63% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.36% of the stock is owned by company insiders.

Insulet Stock Up 1.1%

Shares of PODD opened at $161.55 on Wednesday. The business’s fifty day moving average price is $154.02 and its two-hundred day moving average price is $213.57. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49. The firm has a market capitalization of $11.19 billion, a price-to-earnings ratio of 37.57, a PEG ratio of 1.11 and a beta of 1.11. Insulet Corporation has a 52 week low of $138.79 and a 52 week high of $354.88.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. During the same period in the prior year, the company posted $1.02 EPS. The company’s revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, analysts predict that Insulet Corporation will post 6.46 earnings per share for the current year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.